Biotech Co. Wins $16.5M In Multiple Sclerosis Drug Fight

By Caroline Simson · October 17, 2022, 4:47 PM EDT

Acorda Therapeutics has been awarded $16.5 million by an arbitral panel following a dispute with Irish pharmaceutical company Alkermes over licensing royalties for the multiple sclerosis drug Ampyra, the New York-based...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Caroline

May 20, 2024
Justices Turn Away Hospital Construction Feud
May 15, 2024
High Court Urged To Take Up Hospital Construction Feud
May 03, 2024
BVI Co. Looks To Force $195M PPE Fight Into Arbitration
April 05, 2024
Equatorial Guinea Says $8M Award Can't Be Enforced
April 04, 2024
NY AG Asked To Weigh In On Multiple Sclerosis Drug Fight
March 21, 2024
UpHealth Claims $110M Win In Glocal Control Fight
March 19, 2024
Acorda Says Tribunal Ignored Patent Law In MS Drug Feud
March 04, 2024
French Spinal Care Co. Can't Get €4.2M Award Enforced
November 20, 2023
DC Judge OKs $8M Award Against Equatorial Guinea
October 20, 2023
Arbitrator Misconduct Sinks $10M Nursing Home Sale Award